CommercialCoverageMedium impact
06.02.04d, Fetal Fibronectin Enzyme (fFN) Immunoassay
Independence Blue Cross·OB-GYN·Medical Policy
Effective date
Sep 5, 2025
We identified it
Jun 19, 2026
Summary
The fetal fibronectin enzyme (fFN) immunoassay policy has been archived and is no longer active for commercial plans. This indicates the policy has been removed from active use, potentially affecting coverage or billing procedures for this prenatal diagnostic test.
Action Required
By September 5, 2025: Billing team must verify current coverage requirements for fetal fibronectin testing with commercial payers since the previous policy has been archived. Contact insurance verification team to confirm alternative coverage pathways or updated policies for fFN immunoassays before billing these services.